top of page


Recognizing Grief and the Need for Support
November 17th is National Grief and Bereavement Day This National Grief and Bereavement Day, our friends at the Canadian Hospice Palliative Care Association are calling on governments, organizations, healthcare providers, and community leaders to #ShineALight and recognize grief as a public health issue. They are advocating for greater investment in the resources, services, and education needed to support people who are grieving. Grief touches everyone and every community, ye

PHA Canada
19 minutes ago1 min read
Prevalence of high probability of PH in early systemic sclerosis
In patients with early systemic sclerosis or systemic sclerosis without cutaneous involvement, 26% had a high probability of pulmonary hypertension (PH), most often pulmonary arterial hypertension. Screening for pulmonary hypertension early in the course of systemic sclerosis may help identify PH sooner. Read the Revista Colombiana de Reumatología (English edition) article
Robyn Kalda
1 day ago1 min read


Scleroderma - Hard word, harder to fight alone
Raising another generation of patient advocates At the end of October, PHA Canada had the pleasure of being invited back to the 42nd annual Scleroderma BC conference in Burnaby. For those who don’t know, scleroderma is an autoimmune condition that often involves hardening of the blood vessels, which we know can lead to pulmonary arterial hypertension. The Scleroderma Association of BC (SABC)’s president Cecille Soriano and I connected last year over our mutual stories of bein
Kate Salonga, Patient
Nov 92 min read
Systematic review of treatment strategies to reach low-risk status in PH
A systematic review examined the evidence linking individual pulmonary hypertension treatment strategies to low-risk status and long-term outcomes. 48 reports were included. Few patients reached low-risk status. Prostacyclin pathway therapy and add-on sotatercept improved clinical outcomes. Low-risk status predicted survival, but people initially at low risk did not often stay low risk: the risk category at their first annual review predicted the later disease course. Studies
Robyn Kalda
Nov 91 min read


PHA Canada at The Inside Affair
On October 22, Kim and I were invited to attend the 15th anniversary of the Gastrointestinal Society’s annual fundraising gala/dinner, which also celebrated their 50th anniversary as an organization. I know what you’re thinking – why on earth would we, an organization that represents patients with lung-related diseases, be invited to an event that represents patients with digestive-tract diseases? And why would we even want to attend? This is where community engagement and a
Joan Paulin - Board member
Nov 22 min read


Unsilencing pain
November 2-8 is National Pain Awareness Week. This year’s campaign, #UnsilencePain, invites all of us to help carry that work forward in everyday conversations. Pulmonary hypertension (PH) patients are no strangers to pain, whether it’s chest pain from PH itself or pain as a side effect of medications. Like fatigue or shortness of breath, pain is one of the “invisible” symptoms of PH. But what is pain and where does it come from? A recent article in The Tyee says: “’It’s not

PHA Canada
Nov 22 min read
Using antithrombotics in children with PH
A study used US registry data and a survey to explore the usage of antithrombotic therapy in children with pulmonary hypertension (PH). Antithrombotic therapy is used infrequently in pediatric PH and is primarily reserved for high-risk patients, with significant variation across centers. Survey data generally agreed that antithrombotic therapy was not indicated for patients at the lowest risk and was probably indicated for patients at the highest risk, but management of inter
Robyn Kalda
Nov 21 min read
Make the Connection: Helping Canadians Living with Pulmonary Hypertension Find Support Beyond the Appointment
This November, PHA Canada calls on healthcare professionals to connect patients and caregivers with resources, education, and community support. Vancouver, BC (November 1, 2026) — A medical appointment is an essential part of pulmonary hypertension care. But when patients return home, questions, emotional challenges, and the demands of daily life continue. This Pulmonary Hypertension Awareness Month, the Pulmonary Hypertension Association of Canada (PHA Canada) is asking heal

PHA Canada
Nov 12 min read


In the news: Lisa Harder talks about clinical trials
Patient partner and PHA Canada Knowledge Philanthropist Lisa Harder was in the news twice recently, talking about her experience with the sotatercept clinical trial. University of Alberta Folio: New program aims to fast-track clinical trials across the province (September 24) CBC Alberta at Noon: Clinical trials (August 17) Thank you for sharing your experiences, Lisa, and congratulations on the media coverage! Find out more about clinical trials in Canada

PHA Canada
Oct 281 min read
Selexipag side effects are associated with hemodynamic responses
A Japanese study examined whether selexipag side effects were associated with hemodynamic responses and found that headaches might be associated with treatment responsiveness and a better prognosis through mPAP reduction. Read the Therapeutic Advances in Respiratory Disease article
Robyn Kalda
Oct 261 min read


It's in the Genes: How Genetics Is Reshaping Our Understanding of PAH
Many health awareness campaigns around the world attribute the progression of diseases to environmental and lifestyle factors; however, genetics is often forgotten. For many diseases, a patient’s genetics is an important biological driver. Genetics is a branch of biology focusing on genes, heredity and genetic variation. All of these combine to explain how traits and diseases can be passed from parents to their children through DNA. In a consensus report summarizing the 7th
Dhaval Thanavala
Oct 212 min read
Patient and Clinician Views on Shared Decision-Making
Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%) and efficacy of therapy (42% vs. 29%), whereas clinicians prioritized risk of disease progression (67% vs. 30%). Although 92% of clinicians reported eliciting patient values, only 75% of patients perceived that this occurred. There is a discordance in treatment priorities betwe
Robyn Kalda
Oct 211 min read


Pulmonary Hypertension Global Patient Survey
In 2023, the Pulmonary Vascular Research Institute (PVRI) launched a Pulmonary Hypertension Global Patient Survey. The first global survey of those living with pulmonary hypertension (PH) and their caregivers, it aimed to help clinicians better understand the impacts of pulmonary hypertension on patients. Pulmonary hypertension affects people of all ages, genders and demographics, so a truly global response is required. As the only global pulmonary vascular disease charity, t

PHA Canada
Oct 212 min read


What You Can't See: Understanding Invisible Disability
This week, October 18th to 24th, marks Invisible Disabilities Awareness Week. When we think of disability, we often imagine wheelchairs, casts or another visible cue. But not every disease comes with a visible sign; there may not be an obvious sign telling the world that someone is fighting hard to get through the day. Pulmonary Hypertension (PH) is a prime example. On the surface, a person living with PH may look completely healthy, but inside, their heart and lungs are fi
Dhaval Thanavala
Oct 192 min read
Why lived experience must shape research
"Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that lived experience must shape research from the outset, and discuss how genuine patient-researcher partnership transforms science, care and identity." Read the PLOS Medicine article
Robyn Kalda
Oct 191 min read


Mosliciguat PHocus study succeeds, and other pharma news
PHocus study succeeds The PHocus study, a Phase 2 trial evaluating the safety and effectiveness of the new drug mosliciguat for pulmonary hypertension associated with interstitial lung disease. (PH-ILD), reported good results. After 16 weeks of taking mosliciguat, participants’ pulmonary vascular resistance dropped by over half, their six-minute walk distance increased by 35m, and their NTproBNP level also dropped by half. Based on these very encouraging results, Pulmovant be

PHA Canada
Oct 131 min read


What do blood clots have to do with pulmonary hypertension?
October 13 is World Thrombosis Day A thrombosis is a blood clot inside a blood vessel, and October 13 is World Thrombosis Day, a global campaign to raise awareness of blood clots and their risk factors. This year’s campaign highlights women’s blood clot risks throughout life, including those associated with hormonal changes, pregnancy, and menopause. Blood clots can have serious consequences, including pulmonary embolism, which occurs when a clot blocks blood flow in the lung

PHA Canada
Oct 132 min read
More than half of pulmonary fibrosis patients have PH
There is not much data looking at pulmonary hypertension (PH) in interstitial lung disease, except in idiopathic pulmonary fibrosis (IPF). A study of patients with pulmonary fibrosis found that 60.7% of those with progressive pulmonary fibrosis (PPF) and 63.8% of those with idiopathic pulmonary fibrosis had pulmonary hypertension. Read the Respiratory Investigation article
Robyn Kalda
Oct 121 min read


Real voices, real change: listening to lived experience with mental health
October 10 is World Mental Health Day When we talk about pulmonary hypertension (PH), we often focus on symptoms, medications, side effects, and medical appointments, but taking care of yourself when you have PH means looking after more than your physical symptoms. Your mental health matters, too. Acknowledging the emotional impact of PH tells a more complete story. Talking openly about mental health helps normalize the emotional challenges that can come with a chronic illnes

PHA Canada
Oct 92 min read
Frequent imaging of children with PH may lead to high radiation doses
A 41-study review of children with non-cancer chronic diseases looked at how much radiation they were exposed to during their relatively frequent medical imaging. Children with PH were included. The review found that plain x-rays did not lead to significant radiation accumulation, but CT scans and flouroscopy led to much higher accumulation. Read the review in Pediatric Radiology
Robyn Kalda
Oct 51 min read
bottom of page
